Analysts expect Pfizer (PFE) to see adjusted EPS of $0.74 in Q2 2018. They expect its revenue to grow 3% YoY (year-over-year) to $13.3 billion from $12.9 billion, and its adjusted net income to grow 9.5% YoY, mainly due to lower SG&A (selling, general, and administration) and R&D (research and development) expenses. The chart below shows analysts’ recommendations for Pfizer stock over the last 12 months.
Pfizer stock has risen ~7.1% over the last 12 months and 0.2% so far this year. Analysts’ 12-month target price of $39.86 suggests a ~9.8% return over the next 12 months based on the stock’s June 21 price of $36.30.
Of the 22 analysts tracking Pfizer on June 22, two recommended “strong buy,” ten recommended “buy,” eight recommended “hold,” and two recommended “strong sell.” Their consensus rating of 2.6 represents a moderate “buy” for value investors.
Check out all the data we have added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!